Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
South Africa
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Angiomax
2. Angiomax Rtu
3. Bg 8967
4. Bg-8967
5. Bg8967
6. Bivalirudin Trifluoroacetate
7. Ctb-001
8. Hirulog
9. Hirulog-1
10. L-leucine, D-phenylalanyl-l-prolyl-l-arginyl-l-prolylglycylglycylglycylglycyl-l-asparaginylglycyl-l-alpha-aspartyl-l-phenylalanyl-l-alpha-glutamyl-l-alpha-glutamyl-l-isoleucyl-l-prolyl-l-alpha-glutamyl-l-alpha-glutamyl-l-tyrosyl-
11. Phe-pro-arg-pro-(gly)4 Desulfato-tyr63'-hirugen
12. Phe-pro-arg-pro-(gly)4-asn-gly-asp-phe-glu-glu-ile-pro-glu-glu-tyr-leu
13. Phe-pro-arg-pro-(gly)4-desulfohirudin-(53-64)
1. 128270-60-0
2. Angiomax
3. Bivalirudin Trifluoroacetate
4. Bg-8967
5. Bg8967
6. Hirulog
7. Chebi:59173
8. Hirulog-1
9. D-phenylalanyl-l-prolyl-l-arginyl-l-prolylglycylglycylglycylglycyl-l-asparaginylglycyl-l-alpha-aspartyl-l-phenylalanyl-l-alpha-glutamyl-l-alpha-glutamyl-l-isoleucyl-l-prolyl-l-alpha-glutamyl-l-alpha-glutamyl-l-tyrosyl-l-leucine
10. L-leucine, D-phenylalanyl-l-prolyl-l-arginyl-l-prolylglycylglycylglycylglycyl-l-asparaginylglycyl-l-alpha-aspartyl-l-phenylalanyl-l-alpha-glutamyl-l-alpha-glutamyl-l-isoleucyl-l-prolyl-l-alpha-glutamyl-l-alpha-glutamyl-l-tyrosyl-
11. Angiox
12. Bivalirudina
13. Bivalirudine
14. Bivalirudinum
15. Bg 8967
16. Unii-tn9bex005g
17. Bivalirudin [usan:inn:ban]
18. Bivalirudin Tfa
19. 1191386-55-6
20. Hs-2004
21. Tn9bex005g
22. Schembl25739
23. Gtpl6470
24. Bivalirudin Trifluoroacetate Salt
25. Chembl2103749
26. Dtxsid00155847
27. Bivalirudin;0.9% Sodium Chloride
28. Ex-a5843
29. Bdbm50248103
30. Mfcd08692016
31. Akos015994644
32. Db00006
33. 70b600
34. 270b600
35. J-005587
36. Q4919218
37. Bivalirudin Trifluoroacetate (h-dl-phe-dl-pro-dl-arg-dl-pro-gly-gly-gly-gly-dl-asn-gly-dl-asp-dl-phe-dl-glu-dl-glu-xiile-dl-pro-dl-glu-dl-glu-dl-tyr-dl-leu-oh.tfa)
Molecular Weight | 2180.3 g/mol |
---|---|
Molecular Formula | C98H138N24O33 |
XLogP3 | -7.1 |
Hydrogen Bond Donor Count | 28 |
Hydrogen Bond Acceptor Count | 35 |
Rotatable Bond Count | 67 |
Exact Mass | 2179.9891678 g/mol |
Monoisotopic Mass | 2178.9858129 g/mol |
Topological Polar Surface Area | 902 Ų |
Heavy Atom Count | 155 |
Formal Charge | 0 |
Complexity | 4950 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 16 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Angiomax |
PubMed Health | Bivalirudin (Injection) |
Drug Classes | Anticoagulant |
Drug Label | Angiomax is a specific and reversible direct thrombin inhibitor. The active substance is a synthetic, 20amino acid peptide. The chemical name is D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparagyl-glycyl-L-aspartyl-L-... |
Active Ingredient | Bivalirudin |
Dosage Form | Injectable |
Route | Intravenous |
Strength | 250mg/vial |
Market Status | Prescription |
Company | Medicines |
2 of 4 | |
---|---|
Drug Name | Bivalirudin |
PubMed Health | Bivalirudin (Injection) |
Drug Classes | Anticoagulant |
Drug Label | Angiomax is a specific and reversible direct thrombin inhibitor. The active substance is a synthetic, 20amino acid peptide. The chemical name is D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparagyl-glycyl-L-aspartyl-L-... |
Active Ingredient | Bivalirudin |
Dosage Form | Injectable |
Route | injection |
Strength | 250mg |
Market Status | Tentative Approval |
Company | Hospira |
3 of 4 | |
---|---|
Drug Name | Angiomax |
PubMed Health | Bivalirudin (Injection) |
Drug Classes | Anticoagulant |
Drug Label | Angiomax is a specific and reversible direct thrombin inhibitor. The active substance is a synthetic, 20amino acid peptide. The chemical name is D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparagyl-glycyl-L-aspartyl-L-... |
Active Ingredient | Bivalirudin |
Dosage Form | Injectable |
Route | Intravenous |
Strength | 250mg/vial |
Market Status | Prescription |
Company | Medicines |
4 of 4 | |
---|---|
Drug Name | Bivalirudin |
PubMed Health | Bivalirudin (Injection) |
Drug Classes | Anticoagulant |
Drug Label | Angiomax is a specific and reversible direct thrombin inhibitor. The active substance is a synthetic, 20amino acid peptide. The chemical name is D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparagyl-glycyl-L-aspartyl-L-... |
Active Ingredient | Bivalirudin |
Dosage Form | Injectable |
Route | injection |
Strength | 250mg |
Market Status | Tentative Approval |
Company | Hospira |
For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
FDA Label
Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment-elevation myocardial infarction (STEMI) undergoing primary PCI.
Angiox is also indicated for the treatment of adult patients with unstable angina / non-ST-segment-elevation myocardial infarction (UA / NSTEMI) planned for urgent or early intervention.
Angiox should be administered with aspirin and clopidogrel.
Bivalirudin mediates an inhibitory action on thrombin by directly and specifically binding to both the catalytic site and anion-binding exosite of circulating and clot-bound thrombin. The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin.
Antithrombins
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. (See all compounds classified as Antithrombins.)
B01AE06
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AE - Direct thrombin inhibitors
B01AE06 - Bivalirudin
Absorption
Following intravenous administration, bivalirudin exhibits linear pharmacokinetics. The mean steady state concentration is 12.3 +/- 1.7mcg/mL after administration of an intravenous bolus of 1mg/kg followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.
Route of Elimination
Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.
Volume of Distribution
0.2L/kg
Clearance
3.4 mL/min/kg [Normal renal function]
3.4 mL/min/kg [mild renal function]
2.7 mL/min/kg [moderate renal function]
2.8 mL/min/kg [severe renal function]
1 mL/min/kg [Dialysis-dependent patients]
80% proteolytic cleavage
Normal renal function: 25 min (in normal conditions)
Creatinine clearance 10-29mL/min: 57min
Dialysis-dependant patients: 3.5h
Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Bivalirudin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bivalirudin, including repackagers and relabelers. The FDA regulates Bivalirudin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bivalirudin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bivalirudin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bivalirudin supplier is an individual or a company that provides Bivalirudin active pharmaceutical ingredient (API) or Bivalirudin finished formulations upon request. The Bivalirudin suppliers may include Bivalirudin API manufacturers, exporters, distributors and traders.
click here to find a list of Bivalirudin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bivalirudin DMF (Drug Master File) is a document detailing the whole manufacturing process of Bivalirudin active pharmaceutical ingredient (API) in detail. Different forms of Bivalirudin DMFs exist exist since differing nations have different regulations, such as Bivalirudin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bivalirudin DMF submitted to regulatory agencies in the US is known as a USDMF. Bivalirudin USDMF includes data on Bivalirudin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bivalirudin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bivalirudin suppliers with USDMF on PharmaCompass.
A Bivalirudin written confirmation (Bivalirudin WC) is an official document issued by a regulatory agency to a Bivalirudin manufacturer, verifying that the manufacturing facility of a Bivalirudin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Bivalirudin APIs or Bivalirudin finished pharmaceutical products to another nation, regulatory agencies frequently require a Bivalirudin WC (written confirmation) as part of the regulatory process.
click here to find a list of Bivalirudin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bivalirudin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bivalirudin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bivalirudin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bivalirudin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bivalirudin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bivalirudin suppliers with NDC on PharmaCompass.
Bivalirudin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bivalirudin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bivalirudin GMP manufacturer or Bivalirudin GMP API supplier for your needs.
A Bivalirudin CoA (Certificate of Analysis) is a formal document that attests to Bivalirudin's compliance with Bivalirudin specifications and serves as a tool for batch-level quality control.
Bivalirudin CoA mostly includes findings from lab analyses of a specific batch. For each Bivalirudin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bivalirudin may be tested according to a variety of international standards, such as European Pharmacopoeia (Bivalirudin EP), Bivalirudin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bivalirudin USP).
LOOKING FOR A SUPPLIER?